ADC Analytical Development
&
Quality Control
Build an analytical program that helps teams understand the molecule, guide
development decisions, and move with confidence from early characterization to commercial release.
Product Quality & Compliance Excellence Analytical Strategy Across the Full ADC Development Path
ADC analytical strategy has to account for the antibody, the linker-payload, and the final conjugated product as one quality story. DES Pharma helps sponsors build analytical development and QC programs that support DAR control, conjugation heterogeneity assessment, free payload monitoring, unconjugated antibody measurement, potency, purity, and stability across the full development path.
For ADCs, the right method set depends on the question being asked and the stage of the program. HIC-HPLC, RP-HPLC, SEC-HPLC, LC-MS, intact mass, peptide mapping, CE-SDS, and cell-based potency assays all have a place when they are selected with a clear purpose. We help teams choose, develop, qualify, transfer, and maintain methods that remain useful from early development through GMP QC and regulatory submission.
ADC Analytical & QC Focus Areas
Where analytical work creates the most value for ADC programs
Our analytical work concentrates on clear DAR understanding, practical impurity testing, useful potency assays, and a realistic path from development into QC.
DAR Profiling & Drug Load Distribution
HIC-HPLC / RP-HPLC / SEC-HPLC / CE-SDS
Free Payload & Residual Linker Analysis
Unconjugated Antibody Assessment
Aggregate & Fragment Monitoring
Potency & Bioassay Strategy
Linker Stability & Forced Degradation
Representative Analytical Services
- Intact mass and subunit mass characterization
- Peptide mapping for conjugation-site confirmation
- Residual free payload assay development
- DAR trend monitoring across scale and site changes
- Potency assay qualification planning by development stage
- Stability program analytical panel design
Analytical Control Strategy
Critical Quality Attributes &
Recommended Control Methods
ADC control strategy works best when orthogonal methods are used to answer specific
quality questions around identity, drug loading, purity, potency, and stability. One assay rarely
tells the full story.
Analytical Control Strategy Critical Quality Attributes & Recommended Control Methods
| Analytical Focus Area | Analytical Approach / Considerations |
|---|---|
| DAR & Drug Load Distribution | HIC-HPLC, RP-HPLC, and LC-MS methods to define average DAR and the distribution of loaded species, from DAR0 (unconjugated) through high-loaded fractions. |
| Intact Mass Confirmation | High-resolution LC-MS to confirm conjugate mass profile and assess overall load state, identifying major and minor conjugated species at the intact protein level. |
| Conjugation Site Characterization | Peptide mapping and reduced-chain or subunit mass analysis for site occupancy and heterogeneity, critical for site-specific conjugation platform characterization and IND filing support. |
| Free Payload & Residual Linker-Payload | Reverse-phase methods with sensitivity adequate for low-level residual species and process carryover, with limits established based on payload potency and ICH Q3A/Q3B thresholds. |
| Unconjugated Antibody | Orthogonal chromatographic methods, including HIC-HPLC and affinity-based approaches, to quantify DAR0 species within the ADC bulk and support purification process characterization. |
| Aggregates & Fragments | SEC-based monitoring as the primary method, supported by orthogonal approaches such as DLS, AUC, or AF4 when structural clarification of higher-order species is needed. |
| Potency | Cell-based cytotoxicity, binding, internalization, or other mode-of-action-based assays suitable for the product stage, with qualification and validation planning aligned to ICH Q2(R2) and current bioassay expectations. |
| Linker Stability | Stress and real-time stability-indicating methods tracking deconjugation, payload release, or related degradation, with forced degradation study design aligned to the linker chemistry and payload class. |
Our Frameworks
Guiding Analytical Strategy Through Data
AD & QC Services for ADC Programs
Analytical Development and Quality Control serve different but connected functions. We build programs where both frameworks reinforce each other, so methods developed in AD are ready to transfer and use in QC.
Analytical Development
Method design, development, and characterization strategy
- Phase-appropriate analytical targets for DAR, payload-related impurities, potency, and stability
- Method screening for DAR, residual free drug, conjugation-site distribution, and aggregate risk
- Orthogonal characterization strategy using chromatography and mass spectrometry
- Reference standard and system suitability planning for the ADC method lifecycle
- Stability-indicating method development for linker integrity and payload retention
- Filing-ready method summaries, development reports, and transfer packages
Quality Control
Release testing, method lifecycle, and QC program governance
- Release panel design for identity, purity, potency, DAR, and residual free payload
- Specification justification based on development data, product knowledge, and clinical relevance
- Qualification and validation planning under ICH Q14 and ICH Q2(R2)
- Transfer oversight for internal QC labs, CDMOs, and contract testing sites
- Trending, OOS, OOT, and CAPA support for ADC analytical programs
- Data integrity and documentation structure suitable for inspection and submission review
Integrated Analytical CMC Analytical Strategy That Carries Into QC
A good ADC analytical package does more than generate test results. It shows how process choices affect product quality and gives technical, quality, and regulatory teams a clearer basis for decision-making. DES Pharma builds analytical strategies that connect early characterization work with later QC use, so the methods selected at the start remain practical to qualify, transfer, validate, and maintain in a GMP setting.
DAR Understanding
DAR analysis is linked to process interpretation and product performance, so chromatographic data informs both manufacturing decisions and specification design, not just batch release.
Practical Impurity Assays
Methods for free payload, linker-related species, fragments, and aggregates built around realistic sensitivity targets, practical sample handling, and GMP-compatible workflows.
Potency Strategy
Bioassay design aligned with the ADC's mode of action and stage of development, from early relative potency assays through validated QC bioassays suitable for commercial release.
Stability Insight
Linker integrity monitoring, payload release risk profiling, and degradation pathway characterization to support shelf-life justification, storage condition selection, and comparability strategies.
QC Transferability
Transferability criteria, system suitability parameters, and method performance acceptance limits are built into analytical development, so transfer to CDMOs and contract labs is straightforward, not remedial.
Why DES Pharma for ADC Analytics
Driving Data-Backed Decisions
At Every Stage of Development
Our analytical consulting integrates scientific depth with QC practicality, so the work done in development becomes an asset in GMP operations and regulatory review.
Fit-for-Purpose Methods
Methods designed around the decision each development stage actually needs, not a fixed panel applied regardless of molecule, platform, or program maturity.
Orthogonal Characterization
Critical quality attributes evaluated using multiple independent techniques so no single method carries the entire quality picture for a complex conjugated molecule.
Transfer-Ready QC Thinking
QC transferability is built into analytical development from the start, reducing the rework, OOS investigations, and timeline delays that arise when QC requirements are addressed late.
Lifecycle-Aligned Strategy
Method development through validation and ongoing maintenance framed as a connected program under ICH Q14 and Q2(R2) analytical lifecycle expectations.
Comparability Support
Analytical comparability packages for process changes, site transfers, scale changes, and material updates, with the documentation depth needed for CMC filings and post-approval variations.
Decision-Focused Data
Analytical outputs structured to help technical, quality, and regulatory teams move forward, not just data packages that meet a minimum test panel requirement.
Analytical Package Design Representative ADC Analytical Package
A complete ADC analytical program addresses the full quality profile of the conjugate, from structural identity and drug loading through purity, potency, and real-time stability monitoring.
Identity & Structural Confirmation
Intact mass, subunit mass, and peptide mapping to confirm conjugate identity, conjugation site occupancy, and structural integrity at each development stage.
DAR & Conjugation Heterogeneity
Average DAR, drug load distribution, and species-level characterization using orthogonal methods, linked to process control targets and specification development.
Purity Profile
Aggregate, fragment, unconjugated antibody, and high-DAR species monitoring, with orthogonal support when SEC alone is insufficient for structural resolution.
Residual Free Payload & Process Impurities
Sensitive RP-based methods for free drug and related linker-payload species, with limits grounded in payload potency, safety data, and regulatory impurity thresholds.
Potency & Binding Characterization
Stage-appropriate potency assays from early relative bioassays through qualified or validated GMP QC methods, aligned to the product's mechanism of action.
Stability-Indicating Methods
Release and shelf-life stability panels covering DAR stability, linker integrity, aggregate formation, payload retention, and potency maintenance under ICH storage conditions.
Get Started Build an ADC Analytical Strategy That Supports Development, Transfer, and QC Use
Connect with our analytical team to discuss your DAR control approach,
potency strategy, method lifecycle plan, or QC transfer readiness.